Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

Summit, Akeso's China approval celebration cut short as survival benefit degrades

17 August 2026 · By · Wire by Fusion42

Published

17 August 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

China

◆ Source

Read at biospace.com →

◆ Verified

Fusion42 · 17 August 2026 · Fusion42 review

Summit Therapeutics and partner Akeso received China's NMPA approval for ivonescimab in treating advanced squamous NSCLC, but updated data shows a decline in progression-free survival, dampening enthusiasm and delaying expected FDA accelerated approval and US launch prospects.

This Wire brief sits within Fusion42's coverage of Biotech.

◆ ◆ The Wire takeaway

The hurdle for lung cancer drug approval just tightened in China, forcing you to rethink timing for FDA clearance and US launch plans for PD-1/VEGF therapies like ivonescimab.

◆ Coverage

1 source · 17 Aug 2026

◆ Related on Wire

◆ Topics

Biotechchina-nmpansclcdrug-label-updateclinical-trialsivonescimab